Nektar Therapeutics (NKTR +0.3%) initiates a
Phase 1 clinical trial evaluating NKTR-255 in patients with
relapsed/refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM).
The study will also assess the combination of NKTR-255 with multiple targeted antibodies.
NKTR-255 is designed to activate the
interleukin-15 (IL-15) pathway which boosts the immune response to
cancer by inducing the proliferation of natural killer cells and memory
CD8+ T cells.
https://seekingalpha.com/news/3506152-nektar-launches-early-stage-study-nktrminus-255-blood-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.